Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, MD, Francesco Turturro, MD, Denái R. Milton, Martin Korbling, MD, Barry I Samuels, BA, MD, Elias J. Jabbour, MD, Celina Ledesma, BS, Rosamar B Valverde, Hui Gao, PhD, Michelle A Fanale, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, James M Reuben, BS, MBA, MS, PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 5814.

https://doi.org/10.1182/blood.V128.22.5814.5814

Published: 2016

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Blood (2012) 119 (26): 6373–6378.

https://doi.org/10.1182/blood-2012-03-417808

Published: 2012

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Journal Articles

12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,

Zaher I Chakhachiro, MD, Rima M Saliba, Ph.D., Grace-Julia Okoroji, Martin Korbling, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Marcos De Lima, MD, Paolo Anderlini, MD, Uday Popat, M.D., Barry I Samuels, MD, L. Jeffrey Medeiros, MD, Carlos E. Bueso-Ramos, MD, PhD, Richard Champlin, MD, Issa F Khouri, MD

Blood (2011) 118 (21): 4138.

https://doi.org/10.1182/blood.V118.21.4138.4138

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Blood (2008) 111 (12): 5530–5536.

https://doi.org/10.1182/blood-2008-01-136242

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Martin Korbling, MD, Chitra Hosing, MD, Luis Fayad, MD, Ming S. Lee, MD, Felipe Samaniego, MD, Barry I. Samuels, MD, Daniel Couriel, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Richard E. Champlin, MD

Blood (2007) 110 (11): 485.

https://doi.org/10.1182/blood.V110.11.485.485

Published: 2007

Journal Articles

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Blood (2006) 108 (11): 315.

https://doi.org/10.1182/blood.V108.11.315.315

Published: 2006

Journal Articles

The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT).

Amin M. Alousi, MD, Rima M. Saliba, PhD, Grace-Julia Okoroji, MS, BS, Chitra Hosing, M.D., Barry I. Samuels, M.D., Richard E. Champlin, M.D., Issa F. Khouri, M.D.

Blood (2006) 108 (11): 3058.

https://doi.org/10.1182/blood.V108.11.3058.3058

Published: 2006

Journal Articles

ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemoimmunotherapy.

Issa F. Khouri, MD, Rima M. Saliba, PHD, Joan Admirand, MD, Susan O’Brien, MD, Ming-S. Lee, MD, Barry I. Samuels, MD, Sergio Giralt, MD, Marcos de Lima, MD, Michael J. Keating, MD, Richard E. Champlin, MD, Carlos Bueso-Ramos, MD

Blood (2006) 108 (11): 3028.

https://doi.org/10.1182/blood.V108.11.3028.3028

Published: 2006

Journal Articles

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

Issa F. Khouri, MD, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Sandra A. Acholonu, MPH, Luis E. Fayad, MD, Martin J. Korbling, MD, Celina Saenz, BS, Barbara Pro, MD, Barry I. Samuels, MD, Marcos J. de Lima, MD, Sergio A. Giralt, MD, Anas Younes, MD, Peter W. McLaughlin, MD, Richard E. Champlin, MD

Blood (2005) 106 (11): 48.

https://doi.org/10.1182/blood.V106.11.48.48

Published: 2005

Journal Articles

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Jorge Enrique Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Peter McLaughlin, MD, Anas Younes, MD, Felipe Samaniego, MD, Andre Goy, MD, Andreas H. Sarris, MD, Ph.D., Nam H. Dang, MD, Ph.D., L. Jeffrey Medeiros, MD, Ruth Katz, MD, Harish Gagneja, MD, Barry I. Samuels, MD, Fernando Cabanillas, MD

Blood (2004) 104 (11): 128.

https://doi.org/10.1182/blood.V104.11.128.128

Published: 2004

NARROW

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT).

ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemoimmunotherapy.

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only